Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® for Children with Cystic Fibrosis Ages 2 through 5 Years Old with at Least One F508del Mutation in the CFTR Gene

– With this reimbursement, approximately 100 children with cystic fibrosis in Australia
will become eligible for a CFTR modulator for the first time –

SYDNEY, 29 July 2024 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that as of 1 August…